COMPOUND

Compounds / Bioregulators

Vesugen

Vesugen (Lys-Glu-Asp / KED Tripeptide; vascular bioregulator)

Bioregulators SubQ · Oral · Sublingual Not FDA approved

Khavinson family bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Synthetic tripeptide developed for vascular endothelial regulation; marketed for atherosclerosis prevention and cardiovascular longevity. Most efficacy data is from one Russian lab; independent Western replication is essentially absent. KED sequence is consistent across vendor sources.

At a glance

Routes
SubQ · Oral · Sublingual
Vial sizes
20 mg
Evidence base
3 studies 3 preclinical

Mechanism

Per the Khavinson 'short-peptide bioregulator' hypothesis, KED is proposed to bind the CATC sequence within the MKI67 (Ki-67) gene promoter region in endothelial cells, upregulating proliferation marker Ki-67 expression. Mechanism is contested in mainstream pharmacology because tripeptides are normally degraded in serum within minutes. Reported preclinical effects: stimulation of endothelial cell proliferation (Ki-67 upregulation), reduction of polyploid endothelial cell accumulation in aged vessels, normalization of endothelin-1 expression, SIRT1 pathway modulation, oxidative stress response modulation, vascular contribution to neuroprotection in Alzheimer's mouse model.

Dosing

No standardized human dosing has been established. Every catalogued study for Vesugen is preclinical or a literature review. Amounts used in animal models do not translate directly to humans.

Published evidence

  1. Animal in vivo 2021

    Neuroprotective Effects of Tripeptides: Epigenetic Regulators in Mouse Model of Alzheimer's Disease

    Khavinson VK, Trofimova SV, et al. Biomedicines

    KED contributed to vascular component of neuroprotection in Alzheimer mouse model alongside other tripeptide bioregulators (Pinealon EDR).

  2. Animal in vivo 2016

    KED tripeptide and atherosclerosis / restenosis vasoprotective mechanisms

    Khavinson VK, Lin'kova NS, et al. Bull Exp Biol Med

    KED reduced atherosclerotic plaque progression markers and improved endothelial regeneration in animal models of vascular injury.

  3. In vitro 2014

    Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging (Russian)

    Lin'kova NS, Khavinson VK, et al. Adv Gerontol

    Vesugen / KED stimulated Ki-67 expression in cultured aged human endothelial cells, reducing markers of endothelial senescence.

    PMID 25051766

Reported side effects

Long-term safety unverified outside Russia
Unknown Mild · Khavinson group reports a clean AE profile; no Western replication.

Interactions

  • Cardiogen Synergy

    Vesugen targets endothelium; Cardiogen targets cardiomyocyte. Complementary cardiovascular axis.

  • Pinealon Synergy

    Both tripeptide bioregulators; combined neuro-vascular protection in Alzheimer mouse model.

Reconstitution and storage

20 mg vial; 2-5 mL BAC water. At 4 mg/mL, 100 mcg = 0.025 mL.

Lyophilized: room temp short-term, refrigerate for >30 days. Reconstituted: refrigerate, use within 30 days.

Open the reconstitution calculator for Vesugen